- Home
- RGCO vs CHRS Comparison
RGCO vs CHRS Comparison
Compare RGCO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGCO
- CHRS
- Stock Information
- Founded
- RGCO 1912
- CHRS 2010
- Country
- RGCO United States
- CHRS United States
- Employees
- RGCO N/A
- CHRS N/A
- Industry
- RGCO Oil & Gas Production
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RGCO Utilities
- CHRS Health Care
- Exchange
- RGCO Nasdaq
- CHRS Nasdaq
- Market Cap
- RGCO 221.2M
- CHRS 194.1M
- IPO Year
- RGCO N/A
- CHRS 2014
- Fundamental
- Price
- RGCO $21.35
- CHRS $1.66
- Analyst Decision
- RGCO
- CHRS Strong Buy
- Analyst Count
- RGCO 0
- CHRS 4
- Target Price
- RGCO N/A
- CHRS $4.51
- AVG Volume (30 Days)
- RGCO 9.2K
- CHRS 1.0M
- Earning Date
- RGCO 11-12-2025
- CHRS 11-10-2025
- Dividend Yield
- RGCO 3.86%
- CHRS N/A
- EPS Growth
- RGCO 5.90
- CHRS N/A
- EPS
- RGCO 1.32
- CHRS 1.55
- Revenue
- RGCO $94,120,500.00
- CHRS $272,209,000.00
- Revenue This Year
- RGCO $19.22
- CHRS N/A
- Revenue Next Year
- RGCO $2.97
- CHRS $109.48
- P/E Ratio
- RGCO $16.21
- CHRS $3.23
- Revenue Growth
- RGCO 12.04
- CHRS 52.33
- 52 Week Low
- RGCO $19.06
- CHRS $0.66
- 52 Week High
- RGCO $24.20
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- RGCO 43.26
- CHRS 53.13
- Support Level
- RGCO $21.16
- CHRS $1.64
- Resistance Level
- RGCO $21.94
- CHRS $1.82
- Average True Range (ATR)
- RGCO 0.37
- CHRS 0.10
- MACD
- RGCO -0.02
- CHRS -0.03
- Stochastic Oscillator
- RGCO 16.11
- CHRS 11.54
About RGCO RGC Resources Inc.
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.